Search Results - "Sigal, Darren"

HALO 202: Randomized Phase II Study of PEGPH20 Plus Nab-Paclitaxel/Gemcitabine Versus Nab-Paclitaxel/Gemcitabine in Patients With Untreated, Metastatic Pancreatic Ductal Adenocarcinoma by Hingorani, Sunil R, Zheng, Lei, Bullock, Andrea J, Seery, Tara E, Harris, William P, Sigal, Darren S, Braiteh, Fadi, Ritch, Paul S, Zalupski, Mark M, Bahary, Nathan, Oberstein, Paul E, Wang-Gillam, Andrea, Wu, Wilson, Chondros, Dimitrios, Jiang, Ping, Khelifa, Sihem, Pu, Jie, Aldrich, Carrie, Hendifar, Andrew E

“…Purpose Metastatic pancreatic ductal adenocarcinoma is characterized by excessive hyaluronan (HA) accumulation in the tumor microenvironment, elevating…”
Get full text

The role of Globo H and SSEA-4 in the development and progression of cancer, and their potential as therapeutic targets by Sigal, Darren S, Hermel, David J, Hsu, Pei, Pearce, Tillman

“…Glycans, chains of sugar molecules found conjugated to cell proteins and lipids, contribute to their growth, movement and differentiation. Aberrant…”
Get full text

Protracted complete response after limited checkpoint inhibitor dosing: A case report by Sember, Quinne, Sigal, Darren

“…Immunotherapy is an important modality in the treatment of many types of malignancy. The optimal duration of treatment with immunotherapy in patients with…”
Get full text

In vivo targeting of B-cell lymphoma with glycan ligands of CD22 by Chen, Weihsu C., Completo, Gladys C., Sigal, Darren S., Crocker, Paul R., Saven, Alan, Paulson, James C.

“…Antibody-mediated cell depletion therapy has proven to provide significant clinical benefit in treatment of lymphomas and leukemias, driving the development of…”
Get full text

Non-invasive characterization of human bone marrow stimulation and reconstitution by cell-free messenger RNA sequencing by Ibarra, Arkaitz, Zhuang, Jiali, Zhao, Yue, Salathia, Neeraj S., Huang, Vera, Acosta, Alexander D., Aballi, Jonathan, Toden, Shusuke, Karns, Amy P., Purnajo, Intan, Parks, Julianna R., Guo, Lucy, Mason, James, Sigal, Darren, Nova, Tina S., Quake, Stephen R., Nerenberg, Michael

“…Circulating cell-free mRNA (cf-mRNA) holds great promise as a non-invasive diagnostic biomarker. However, cf-mRNA composition and its potential clinical…”
Get full text

Very long-term eradication of minimal residual disease in patients with hairy cell leukemia after a single course of cladribine by Sigal, Darren S., Sharpe, Robert, Burian, Carol, Saven, Alan

“…Cladribine induces protracted remissions in patients with hairy cell leukemia (HCL). However, many long-term responders ultimately relapse. We sought to…”
Get full text

Simultaneous Loss of Both Atypical Protein Kinase C Genes in the Intestinal Epithelium Drives Serrated Intestinal Cancer by Impairing Immunosurveillance by Nakanishi, Yuki, Duran, Angeles, L’Hermitte, Antoine, Shelton, Phillip M., Nakanishi, Naoko, Reina-Campos, Miguel, Huang, Jianfeng, Soldevila, Ferran, Baaten, Bas J.G., Tauriello, Daniele V.F., Castilla, Elias A., Bhangoo, Munveer S., Bao, Fei, Sigal, Darren, Diaz-Meco, Maria T., Moscat, Jorge

“…Serrated adenocarcinoma, an alternative pathway for colorectal cancer (CRC) development, accounts for 15%–30% of all CRCs and is aggressive and treatment…”
Get full text

Beyond hairy cell: the activity of cladribine in other hematologic malignancies by Sigal, Darren S., Miller, Heather J., Schram, Ethan D., Saven, Alan

“…Before the contemporary development of rationally designed antineoplastic therapies, cladribine was identified as a lymphocyte-specific agent. Its profound…”
Get full text

Comprehensive genomic profiling identifies novel NTRK fusions in neuroendocrine tumors by Sigal, Darren S, Bhangoo, Munveer S, Hermel, Jonathan A, Pavlick, Dean C, Frampton, Garrett, Miller, Vincent A, Ross, Jeffrey S, Ali, Siraj M

“…CGP results from >60,000 cases were screened to identify NTRK fusion events from cases of neuroendocrine tumors. 2417 NET patients from diverse anatomic sites…”
Get full text

An observational study of hospitalized COVID-19 patients with cancer in San Diego county by Hermel, David J, Cham, Jason, Spierling Bagsic, Samantha R, Hong, Lee K, Costantini, Carrie L, Mason, James R, Saven, Alan, Sigal, Darren S

“…To delineate clinical correlates of COVID-19 infection severity in hospitalized patients with malignancy. The authors conducted a retrospective review of all…”
Get full text

Neoadjuvant chemotherapy and radiotherapy outcomes in borderline‐resectable and locally‐advanced pancreatic cancer patients by Botta, Gregory P., Huynh, Tridu R., Spierling‐Bagsic, Samantha R., Agelidis, Alexander, Schaffer, Randolph, Lin, Ray, Sigal, Darren

“…Background There is no agreed upon standard of care for borderline‐resectable pancreatic cancer (BRPC) or locally‐advanced pancreatic cancer (LAPC) patients…”
Get full text

Targeting B lymphoma with nanoparticles bearing glycan ligands of CD22 by Chen, Weihsu C., Sigal, Darren S., Saven, Alan, Paulson, James C.

“…Abstract CD22 is a member of the siglec (sialic acid-binding immunoglobulin-like lectin) family expressed on B cells that recognizes glycans of glycoproteins…”
Get full text

Checkpoint Inhibition in the Treatment of Unresectable, Advanced Lymphoepithelioma-like Hepatocellular Carcinoma by Hermel, David J, Du, Emma Z, Lin, Ray, Frenette, Catherine T, Sigal, Darren S

“…Lymphoepithelioma-like hepatocellular carcinoma (LEL-HCC) is a very rare neoplasm, with distinct epidemiologic, morphologic and clinical characteristics…”
Get full text

Do patients with metastatic pancreatic adenocarcinoma to the lung have improved survival? by Ebrahimi, Aren, Cham, Jason, Puglisi, Leah, De Shadarevian, Melanie, Hermel, David J., Spierling Bagsic, Samantha R., Sigal, Darren

“…Introduction Pancreatic ductal adenocarcinoma (PDAC) is a genetically heterogeneous disease often diagnosed with synchronous metastatic disease involving the…”
Get full text

Development of cladribine at Scripps for hairy cell leukemia and current results by Torrey, Melissa L., Sigal, Darren S., Saven, Alan

“…Hairy cell leukemia (HCL) is an indolent, mature B-cell lymphoproliferative malignancy that clinically manifests as pancytopenia and fibrosis of the bone…”
Get full text

Novel Combination Strategies to Enhance Immune Checkpoint Inhibition in Cancer Immunotherapy: A Narrative Review by Hermel, Jonathan A., Bruni, Cassi M., Sigal, Darren S.

“…Programmed cell death protein-1 (PD-1) is an immune checkpoint receptor that induces and maintains tolerance of T cells, invariant natural killer T (iNKT)…”
Get full text

Cladribine in indolent non-Hodgkin's lymphoma by Sigal, Darren S, Saven, Alan

“…Before the advent of rationally designed targeted antineoplastic therapies, cladribine was identified as a lymphocyte-specific cytotoxic agent. Cladribine is a…”
Get full text

3D genomics identifies previously unreported yet clinically actionable gene fusions and complex rearrangements in a cohort of driver-negative colorectal carcinoma tumors by Sikkink, Kristin, Beck, Alyssa, Schmitt, Anthony, Sigal, Darren

“…e15608 Background: Molecular characterization by next-generation sequencing (NGS) has been unable to detect pathogenic driver mutations in a significant number…”
Get full text

Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1–2 trials by Doebele, Robert C, Drilon, Alexander, Paz-Ares, Luis, Siena, Salvatore, Shaw, Alice T, Farago, Anna F, Blakely, Collin M, Seto, Takashi, Cho, Byung Chul, Tosi, Diego, Besse, Benjamin, Chawla, Sant P, Bazhenova, Lyudmila, Krauss, John C, Chae, Young Kwang, Barve, Minal, Garrido-Laguna, Ignacio, Liu, Stephen V, Conkling, Paul, John, Thomas, Fakih, Marwan, Sigal, Darren, Loong, Herbert H, Buchschacher, Gary L, Garrido, Pilar, Nieva, Jorge, Steuer, Conor, Overbeck, Tobias R, Bowles, Daniel W, Fox, Elizabeth, Riehl, Todd, Chow-Maneval, Edna, Simmons, Brian, Cui, Na, Johnson, Ann, Eng, Susan, Wilson, Timothy R, Demetri, George D

“…Entrectinib is a potent inhibitor of tropomyosin receptor kinase (TRK) A, B, and C, which has been shown to have anti-tumour activity against NTRK gene…”
Get full text

Randomized Phase III Trial of Pegvorhyaluronidase Alfa With Nab-Paclitaxel Plus Gemcitabine for Patients With Hyaluronan-High Metastatic Pancreatic Adenocarcinoma by Van Cutsem, Eric, Tempero, Margaret A, Sigal, Darren, Oh, Do-Youn, Fazio, Nicola, Macarulla, Teresa, Hitre, Erika, Hammel, Pascal, Hendifar, Andrew E, Bates, Susan E, Li, Chung-Pin, Hingorani, Sunil R, de la Fouchardiere, Christelle, Kasi, Anup, Heinemann, Volker, Maraveyas, Anthony, Bahary, Nathan, Layos, Laura, Sahai, Vaibhav, Zheng, Lei, Lacy, Jill, Park, Joon Oh, Portales, Fabienne, Oberstein, Paul, Wu, Wilson, Chondros, Dimitrios, Bullock, Andrea J

“…To evaluate the efficacy and safety of pegvorhyaluronidase alfa (PEGPH20) plus nab-paclitaxel/gemcitabine (AG) in patients with hyaluronan-high metastatic…”
Get full text